Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omni Bio Pharmaceutical has got US patent no.7,807,781, entitled 'Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Viral Infections', from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
Omni Bio said that the new patent is part of the technology licensed to Omni Bio related to one of its technology license agreements with the University of Colorado-Denver.
The New Patent covers the treatment of human immunodeficiency virus-1 (HIV-1) using one or more of 18 new peptides made up of five linked amino acids, as well as, related modifications of these peptides.
According to the company, the new patent will allow Omni Bio to develop treatments using the new peptides without a requirement to obtain additional licenses from third parties.
Omni Bio acting CEO Charles Dinarello said that the issuance of this patent by the USPTO expands their proprietary technology platform and is an important milestone in developing innovative therapies to addresses potentially large and underserved markets.
"The focus of this patent demonstrates that AAT has the potential to address a variety of indications, first and foremost, HIV-1 infection, and opens a proprietary, new and unique frontier for the development of potential new therapeutics in a variety of areas including bacterial as well as viral disorders, biohazards, diabetes and transplant rejection," Dinarello said.